Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2246) 2246
Book Chapter (69) 69
Dissertation (14) 14
Conference Proceeding (3) 3
Web Resource (3) 3
Magazine Article (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1479) 1479
humans (1475) 1475
hyperphosphatemia (1455) 1455
life sciences & biomedicine (1431) 1431
male (811) 811
urology & nephrology (739) 739
female (701) 701
middle aged (518) 518
hyperphosphatemia - etiology (465) 465
hyperphosphatemia - drug therapy (417) 417
aged (410) 410
adult (348) 348
phosphates - blood (345) 345
animals (334) 334
chronic kidney disease (332) 332
renal dialysis (316) 316
hemodialysis (309) 309
phosphates (298) 298
biological and medical sciences (289) 289
medical sciences (277) 277
nephrology (274) 274
hyperphosphatemia - blood (271) 271
kidney failure, chronic - therapy (259) 259
kidney failure, chronic - complications (254) 254
phosphorus - blood (241) 241
kidney diseases (239) 239
risk factors (235) 235
treatment outcome (235) 235
chelating agents - therapeutic use (229) 229
parathyroid hormone (225) 225
sevelamer (223) 223
phosphorus (209) 209
phosphate (205) 205
phosphates - metabolism (205) 205
calcium (204) 204
calcium - blood (187) 187
parathyroid hormone - blood (186) 186
hypocalcemia (177) 177
dialysis (176) 176
chronic kidney failure (174) 174
vitamin d (172) 172
hyperphosphatemia - complications (166) 166
calcification (163) 163
renal insufficiency, chronic - complications (163) 163
renal dialysis - adverse effects (161) 161
mortality (157) 157
kidneys (144) 144
hyperphosphatemia - metabolism (143) 143
hyperphosphatemia - prevention & control (143) 143
nephrology. urinary tract diseases (142) 142
hypercalcemia (137) 137
kidney failure, chronic - blood (136) 136
polyamines - therapeutic use (131) 131
endocrinology & metabolism (129) 129
medicine & public health (128) 128
phosphate binders (128) 128
renal failure (126) 126
time factors (125) 125
hyperparathyroidism (123) 123
hyperphosphatemia - diagnosis (123) 123
lanthanum - therapeutic use (121) 121
phosphate binder (121) 121
vascular calcification (119) 119
lanthanum carbonate (115) 115
care and treatment (113) 113
hyperphosphatemia - therapy (112) 112
aged, 80 and over (110) 110
hypophosphatemia (110) 110
biomarkers - blood (107) 107
patients (106) 106
phosphorus imbalance (103) 103
child (102) 102
general & internal medicine (102) 102
pharmacology & pharmacy (102) 102
calcium carbonate (101) 101
homeostasis (101) 101
rats (99) 99
pediatrics (98) 98
secondary hyperparathyroidism (98) 98
diet (97) 97
fibroblast growth factor 23 (97) 97
medicine, general & internal (97) 97
retrospective studies (96) 96
adolescent (94) 94
analysis (94) 94
prospective studies (93) 93
calcinosis - etiology (91) 91
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (89) 89
intensive care medicine (89) 89
transplantation (89) 89
end-stage renal disease (88) 88
mice (87) 87
hematology (86) 86
renal insufficiency, chronic - therapy (85) 85
hyperphosphatemia - genetics (83) 83
emergency and intensive care: renal failure. dialysis management (82) 82
health aspects (82) 82
medicine (82) 82
nephropathies. renovascular diseases. renal failure (80) 80
cardiovascular diseases - etiology (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2081) 2081
Japanese (73) 73
Spanish (70) 70
German (55) 55
French (45) 45
Portuguese (33) 33
Italian (20) 20
Russian (18) 18
Korean (13) 13
Polish (13) 13
Chinese (6) 6
Czech (4) 4
Danish (3) 3
Turkish (3) 3
Croatian (1) 1
Estonian (1) 1
Finnish (1) 1
Hungarian (1) 1
Indonesian (1) 1
Norwegian (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis‐Hyperphosphatemia Syndrome
by Ramnitz, Mary Scott and Gourh, Pravitt and Goldbach‐Mansky, Raphaela and Wodajo, Felasfa and Ichikawa, Shoji and Econs, Michael J and White, Kenneth E and Molinolo, Alfredo and Chen, Marcus Y and Heller, Theo and Del Rivero, Jaydira and Seo‐Mayer, Patricia and Arabshahi, Bita and Jackson, Malaka B and Hatab, Sarah and McCarthy, Edward and Guthrie, Lori C and Brillante, Beth A and Gafni, Rachel I and Collins, Michael T
Journal of bone and mineral research, ISSN 0884-0431, 10/2016, Volume 31, Issue 10, pp. 1845 - 1854
FAMILIAL TUMORAL CALCINOSIS | HYPEROSTOSIS‐HYPERPHOSPHATEMIA SYNDROME | FIBROBLAST GROWTH FACTOR 23 | HYPERPHOSPHATEMIA | HYPEROSTOSIS-HYPERPHOSPHATEMIA SYNDROME | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Calcinosis - genetics | Humans | Hyperostosis, Cortical, Congenital - therapy | Fibroblast Growth Factors - genetics | Male | Hyperostosis, Cortical, Congenital - pathology | Hyperphosphatemia - pathology | Hyperphosphatemia - blood | Hyperostosis - blood | N-Acetylgalactosaminyltransferases - genetics | Adult | Female | Hyperostosis - pathology | Hyperphosphatemia - therapy | Child | Hyperostosis - genetics | Hyperostosis - therapy | Calcinosis - blood | Hyperostosis, Cortical, Congenital - genetics | Hyperostosis, Cortical, Congenital - blood | Calcinosis - therapy | Glucuronidase - genetics | Adolescent | Hyperphosphatemia - genetics | Calcinosis - pathology | Cohort Studies | Care and treatment | Phosphorus imbalance | Genetic aspects | C-reactive protein | Gene mutations | Index Medicus | hyperostosis-hyperphosphatemia syndrome | Familial tumoral calcinosis | hyperphosphatemia | fibroblast growth factor 23
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
by Isakova, Tamara and Wahl, Patricia and Vargas, Gabriela S and Gutiérrez, Orlando M and Scialla, Julia and Xie, Huiliang and Appleby, Dina and Nessel, Lisa and Bellovich, Keith and Chen, Jing and Hamm, Lee and Gadegbeku, Crystal and Horwitz, Edward and Townsend, Raymond R and Anderson, Cheryl A.M and Lash, James P and Hsu, Chi-yuan and Leonard, Mary B and Wolf, Myles and on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group and CRIC Study Grp and on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group
Kidney international, ISSN 0085-2538, 06/2011, Volume 79, Issue 12, pp. 1370 - 1378
phosphate | FGF23 | chronic kidney disease | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Kidneys | Urinary system involvement in other diseases. Miscellaneous | Nephropathies. Renovascular diseases. Renal failure | Renal failure | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Predictive Value of Tests | Up-Regulation | Biomarkers - urine | Prospective Studies | United States | Humans | Middle Aged | Hyperparathyroidism, Secondary - physiopathology | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Hyperparathyroidism, Secondary - urine | Hyperphosphatemia - blood | Time Factors | Phosphates - urine | Phosphates - blood | Female | Hyperphosphatemia - urine | Renal Insufficiency, Chronic - diagnosis | Severity of Illness Index | Glomerular Filtration Rate | Phosphorus, Dietary - metabolism | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Renal Insufficiency, Chronic - blood | Hyperparathyroidism, Secondary - blood | Hyperparathyroidism, Secondary - diagnosis | Fibroblast Growth Factors - blood | Hyperphosphatemia - etiology | Aged | Hyperparathyroidism, Secondary - etiology | Hyperphosphatemia - physiopathology | Hyperphosphatemia - diagnosis | Renal Insufficiency, Chronic - urine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Activation of the Nrf2‐ARE Signaling Pathway Prevents Hyperphosphatemia‐Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells
by Yao, Li and Wang, Jian and Tian, Bin‐Yao and Xu, Tian‐Hua and Sheng, Zi‐Tong
Journal of cellular biochemistry, ISSN 0730-2312, 12/2017, Volume 118, Issue 12, pp. 4708 - 4715
AUTOPHAGY | HYPERPHOSPHATEMIA‐INDUCED VASCULAR CALCIFICATION | VASCULAR SMOOTH MUSCLE CELL | Nrf2‐ARE SIGNALING PATHWAY | Nrf2-ARE SIGNALING PATHWAY | HYPERPHOSPHATEMIA-INDUCED VASCULAR CALCIFICATION | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Kidney - blood supply | Kidney - pathology | Muscle, Smooth, Vascular - metabolism | Response Elements | Signal Transduction | Myocytes, Smooth Muscle - pathology | Hyperphosphatemia - metabolism | Rats | Vascular Calcification - prevention & control | Male | Vascular Calcification - pathology | Autophagy | Rats, Sprague-Dawley | Hyperphosphatemia - pathology | Vascular Calcification - metabolism | Kidney - metabolism | Muscle, Smooth, Vascular - pathology | Animals | Hyperphosphatemia - prevention & control | NF-E2-Related Factor 2 - metabolism | Myocytes, Smooth Muscle - metabolism | Prevention | Calcification | Smooth muscle | Bone morphogenetic proteins | Phosphorus imbalance | Transmission electron microscopes | Calcification (ectopic) | Cbfa-1 protein | Ion concentration | Kidneys | Bone morphogenetic protein 2 | Calcium | Genes | Phagosomes | Phosphorus | Activation | siRNA | Western blotting | Polymerase chain reaction | Antioxidants | Signal transduction | Biomedical materials | Hyperphosphatemia | Biocompatibility | Phagocytosis | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Use of phosphate-binding agents is associated with a lower risk of mortality
by Cannata-Andía, Jorge B and Fernández-Martín, José L and Locatelli, Francesco and London, Gérard and Gorriz, José L and Floege, Jürgen and Ketteler, Markus and Ferreira, Aníbal and Covic, Adrian and Rutkowski, Boleslaw and Memmos, Dimitrios and Bos, Willem-Jan and Teplan, Vladimir and Nagy, Judit and Tielemans, Christian and Verbeelen, Dierik and Goldsmith, David and Kramar, Reinhard and Martin, Pierre-Yves and Wüthrich, Rudolf P and Pavlovic, Drasko and Benedik, Miha and Sánchez, José Emilio and Martínez-Camblor, Pablo and Naves-Díaz, Manuel and Carrero, Juan J and Zoccali, Carmine
Kidney international, ISSN 0085-2538, 11/2013, Volume 84, Issue 5, pp. 998 - 1008
dialysis | phosphate binders | mineral metabolism | hyperparathyroidism | hyperphosphatemia | mortality risk | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Multivariate Analysis | Prospective Studies | Hyperphosphatemia - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Aged, 80 and over | Cardiovascular Diseases - mortality | Phosphates - blood | Renal Insufficiency, Chronic - mortality | Female | Renal Insufficiency, Chronic - diagnosis | Chelating Agents - therapeutic use | Cardiovascular Diseases - diagnosis | Risk Factors | Proportional Hazards Models | Europe - epidemiology | Treatment Outcome | Biomarkers - blood | Chi-Square Distribution | Renal Insufficiency, Chronic - blood | Propensity Score | Renal Dialysis - adverse effects | Hyperphosphatemia - drug therapy | Aged | Hyperphosphatemia - diagnosis | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Prevention and treatment of hyperphosphatemia in chronic kidney disease
by Vervloet, Marc G and van Ballegooijen, Adriana J
Kidney international, ISSN 0085-2538, 05/2018, Volume 93, Issue 5, pp. 1060 - 1072
phosphate binders | intestinal phosphate absorption | chronic kidney disease | hyperphosphatemia | dietary phosphate | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Risk Reduction Behavior | Humans | Risk Factors | Phosphorus, Dietary - adverse effects | Treatment Outcome | Biomarkers - blood | Phosphorus, Dietary - blood | Renal Insufficiency, Chronic - blood | Renal Insufficiency, Chronic - epidemiology | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Animals | Hyperphosphatemia - prevention & control | Hyperphosphatemia - epidemiology | Phosphates - blood | Recommended Dietary Allowances | Hyperphosphatemia - therapy | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Intervention | Phosphates | Additives | Kidneys | Working groups | Comorbidity | Hemodialysis | Toxicity | Mortality | Clinical trials | Homeostasis | Cardiovascular disease | Studies | Nutrition research | Diet | Phosphate | Hyperphosphatemia | Fast food | Physiology | Kidney diseases | Cardiovascular diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
by Floege, Jürgen and Covic, Adrian C and Ketteler, Markus and Rastogi, Anjay and Chong, Edward M.F and Gaillard, Sylvain and Lisk, Laura J and Sprague, Stuart M and PA21 Study Grp and PA21 Study Group
Kidney international, ISSN 0085-2538, 09/2014, Volume 86, Issue 3, pp. 638 - 647
dialysis | phosphate binder | sevelamer | hyperphosphatemia | PA21 | adherence | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Nausea - chemically induced | Polyamines - adverse effects | Humans | Middle Aged | Induction Chemotherapy | Male | Polyamines - therapeutic use | Patient Dropouts | Renal Insufficiency, Chronic - complications | Diarrhea - chemically induced | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Adult | Female | Maintenance Chemotherapy | Sevelamer | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Constipation - chemically induced | Medication Adherence | Peritoneal Dialysis | Hyperphosphatemia - etiology | Phosphorus - blood | Ferric Compounds - therapeutic use | Hyperphosphatemia - drug therapy | Aged | Ferric Compounds - adverse effects | Index Medicus | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro
by Sage, Andrew P and Lu, Jinxiu and Tintut, Yin and Demer, Linda L
Kidney international, ISSN 0085-2538, 02/2011, Volume 79, Issue 4, pp. 414 - 422
phosphate | gene transcription | hyperphosphatemia | osteopontin | vascular calcification | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Osteopontin - genetics | Nanoparticles - chemistry | Myocytes, Smooth Muscle - pathology | Hyperphosphatemia - metabolism | DNA Primers - genetics | Calcinosis - etiology | Base Sequence | Cell Differentiation | Calcinosis - metabolism | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Calcium Phosphates - pharmacology | Osteogenesis - genetics | Hyperphosphatemia - complications | Bone Morphogenetic Protein 2 - genetics | Cell Line | Microscopy, Electron, Scanning | Nanoparticles - ultrastructure | Up-Regulation - drug effects | Animals | Hyperphosphatemia - genetics | Mice | Calcinosis - pathology | In Vitro Techniques | Calcium Phosphates - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights